Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma

Anticancer Res. 2002 Nov-Dec;22(6B):3489-94.

Abstract

Background: The increase of glucose transport is a distinguishing marker of tumor cells. We hypothesized that a hypopharyngeal carcinoma, characterized by high frequency of lymph node spread or distant metastasis, was associated with glucose transporter 1 (Glut 1) overexpression.

Materials and methods: We investigated the incidence of Glut1 expression by immunostaining in 99 patients with hypopharyngeal carcinoma, and revealed the correlation with the clinical characteristics.

Results: The analysis showed 46 patients (46%) of Glut1 overexpression (> 70% tumor cell stained). Glut1 expression did not correlate with gender, subsite, histological grade, tumor size, lymph node status or stage grouping. The 5-year relapse-free survival (RFS) rate of patients with Glut1 overexpression (> 70%) (35%) was significantly lower than that of patients with low Glut1 expression (< or = 70%) (57%) (p = 0.047). Multivariate analysis showed that advanced tumor stage (stages III and IV) and Glut1 overexpression were predictors of reduced RFS (p = 0.031 and 0.021, respectively).

Conclusion: Glut1 expression is an indicator for predicting the prognosis of hypopharyngeal carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / biosynthesis*
  • Carcinoma, Squamous Cell / metabolism*
  • Carcinoma, Squamous Cell / pathology
  • Disease-Free Survival
  • Female
  • Glucose Transporter Type 1
  • Humans
  • Hypopharyngeal Neoplasms / metabolism*
  • Hypopharyngeal Neoplasms / pathology
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Monosaccharide Transport Proteins / biosynthesis*
  • Multivariate Analysis
  • Neoplasm Staging

Substances

  • Biomarkers, Tumor
  • Glucose Transporter Type 1
  • Monosaccharide Transport Proteins
  • SLC2A1 protein, human